Dermatology

New late-breaking phase 3 data showed success with nemolizumab, an investigational drug designed for targeting IL-31 signaling and aimed at the underlying causes of the condition.

From a novel acne cream to a breakthrough depression drug, a half-dozen agent decisions are coming through in the coming 6 months.

In this MEDcast episode, Dr Chovatiya and Dr Bunick delve into the advancements in targeted treatments for vitiligo, exploring their potential to provide long-term efficacy and durable clinical response.

New phase 2 data indicates safety and efficacy of dersimelagon, suggesting potential development as an oral treatment for erythropoietic protoporphyria and X-linked protoporphyria.

This new data into alopecia areata patients’ associated conditions may require future research into potential causal relationships with such comorbidities.

Analysis of a novel form of the topical drug shows rosacea is benefitted within 2 weeks of daily administration.

An analysis of patients with psoriasis, PsA, or axSpA show risk of MACE with ixekizumab is consistently low.

New research on patients with pemphigus highlighted the heavy mental burden on those with these conditions and the importance of screening for anxiety, depression, and quality of life.

New data drawn from the EUSTAR database made clear several key insights into this subset of systemic sclerosis patients, with survival and skin manifestations being highlighted.

In this Q&A interview with physician assistant Renata Block, Block spoke on some of her thoughts about the recent SDPA conference and its presentations.

This interview featured a discussion with Dr. Mostaghimi, during which he described some of the latest treatments for alopecia, new policies and efforts for patients, and general conference takeaways.

In this interview, physician assistant Hope Cook described some of the major talking points from her conference talk titled ‘Healing PA Burnout.’

In this discussion with HCPLive, Dr. Markowitz spoke about some of the biggest takeaways from her conference presentation on skin cancer treatments.

Ritlecitinib becomes the second JAK inhibitor approved to treat alopecia—and the first to be indicated for patients aged 12 years and older.

Post hoc analysis of the topical therapy show patients receiving treatment for acne in the winter were as likely to achieve benefit as those receiving it in the summer.

In this interview, Dr. Noor spoke about the contents of his conference presentation regarding the tailoring of treatment plans to patients with skin of color.

A post hoc analysis of phase 3 adds support to the IL-17A inhibitor for the potential treatment of HS.

While contact dermatitis is difficult to distinguish in children, there has become a greater collaboration between allergic and dermatologic specialists in managing conditions like atopic dermatitis.

The first triple-combination topical drug for acne may be available by the end of this year. One expert has high hopes for it.

Zirwas touts topical ruxolitinib's rapid, effective treatment of atopic dermatitis, and reviews the safety outcomes associated with JAK inhibitors.

Pigmentary disorders including melasma are difficult to treat and complex. The leading agent for one expert was uncovered by unique circumstances.

Describing the biggest takeaways from her talk ‘Diagnosis and Management of Blistering Disorders,’ Dr. Noe went in depth about treatment of blistering in patients.

From addressing the rare acne fulminans to utilizing narrow-spectrum antibiotics, the modern field of acne treatment is more complicated than it seems.

Analysis of phase 3 trial data show the JAK inhibitor is generally safe among patients with severe forms of the chronic hair loss disease.

In the span of a decade, agents like topical ivermectin, minocycline and benzoyl peroxide has provided more opportunities to achieve clear skin for rosacea patients.